COVID-19 in Pregnant Women With Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance

Bonnie L. Bermas, Milena Gianfrancesco, Helen L. Tanner, Andrea M. Seet, Mathia C. Aguiar, Nasra K. Al Adhoubi, Samar Al Emadi, Bernardo M. Cunha, Rachael Flood, Daria A. Kusevich, Eoghan M. McCarthy, Naomi J. Patel, Eric M. Ruderman, Sebastian E. Sattui, Savino Sciascia, Faizah Siddique, Maria O. Valenzuela-Almada, Leanna M. Wise, Angus B. Worthing, Jo Ann ZellSuleman Bhana, Wendy Costello, Ali Duarte-Garcia, Rebecca Grainger, Laure Gossec, Jonathan S. Hausmann, Kimme Hyrich, Saskia Lawson-Tovey, Jean W. Liew, Emily Sirotich, Jeffrey A. Sparks, Paul Sufka, Zachary S. Wallace, Pedro M. Machado, Anja Strangfeld, Megan E.B. Clowse, Jinoos Yazdany, Philip C. Robinson

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Objective. To describe coronavirus disease 2019 (COVID-19) and pregnancy outcomes in patients with rheumatic disease who were pregnant at the time of infection. Methods. Since March 2020, the COVID-19 Global Rheumatology Alliance has collected cases of patients with rheumatic disease with COVID-19. We report details of pregnant women at the time of COVID-19 infection, including obstetric details separately ascertained from providers. Results. We report on 39 patients, including 22 with obstetric detail available. The mean and median age was 33 years, range 24–45 years. Rheumatic disease diagnoses included rheumatoid arthritis (n = 9), systemic lupus erythematosus (n = 9), psoriatic arthritis/other inflammatory arthritides (n = 8), and antiphospholipid syndrome (n = 6). Most had a term birth (16/22), with 3 preterm births, 1 termination, and 1 miscarriage; 1 woman had yet to deliver at the time of report. One-quarter (n = 10/39) of pregnant women were hospitalized following COVID-19 diagnosis. Two of 39 (5%) required supplemental oxygen (both hospitalized); no patients died. The majority did not receive specific medication treatment for their COVID-19 (n = 32/39, 82%), and 7 patients received some combination of antimalarials, colchicine, anti–interleukin 1β, azithromycin, glucocorticoids, and lopinavir/ritonavir. Conclusion. Women with rheumatic diseases who were pregnant at the time of COVID-19 had favorable outcomes. These data have limitations due to the small size and methodology; however, they provide cautious optimism for pregnancy outcomes for women with rheumatic disease particularly in comparison to the increased risk of poor outcomes that have been reported in other series of pregnant women with COVID-19.

Original languageEnglish (US)
Pages (from-to)110-114
Number of pages5
JournalJournal of Rheumatology
Issue number1
StatePublished - Jan 1 2022


  • COVID-19
  • anti-TNF
  • disease-modifying antirheumatic drug
  • rheumatoid arthritis
  • rheumatology

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'COVID-19 in Pregnant Women With Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance'. Together they form a unique fingerprint.

Cite this